{
    "Trade/Device Name(s)": [
        "Contour Next EZ Blood Glucose Monitoring System"
    ],
    "Submitter Information": "Ascensia Diabetes Care US Inc.",
    "510(k) Number": "K162336",
    "Predicate Device Reference 510(k) Number(s)": [
        "K130265"
    ],
    "Regulatory Class": "Class II",
    "Product Code(s)": [
        "NBW",
        "LFR"
    ],
    "Summary Letter Date": "August 19, 2016",
    "Summary Letter Received Date": "August 22, 2016",
    "Submission Date": "January 4, 2017",
    "Regulation Number(s)": [
        "21 CFR 862.1345"
    ],
    "Regulation Name(s)": [
        "Glucose test system"
    ],
    "Analyte Class(es)": [
        "chemistry"
    ],
    "Analyte(s)": [
        "Glucose"
    ],
    "Specimen Type(s)": [
        "Whole Blood",
        "Capillary Blood (fingertip)"
    ],
    "Specimen Container(s)": [],
    "Instrument(s)/Platform(s)": [
        "Contour Next EZ Blood Glucose Meter"
    ],
    "Method(s)/Technology(ies)": [
        "Amperometric detection",
        "Electrochemical measurement"
    ],
    "Methodologies": [
        "Dry reagent strip",
        "FAD-GDH enzymatic reaction"
    ],
    "Submission Type(s)": [
        "System",
        "Analyzer",
        "Test Strip",
        "Control Solution"
    ],
    "Document Summary": "FDA 510(k) summary for Contour Next EZ Blood Glucose Monitoring System for OTC quantitative measurement of glucose in whole blood",
    "Indications for Use Summary": "Over-the-counter device for self-testing by persons with diabetes at home for the quantitative measurement of glucose in fresh fingertip capillary whole blood; single-patient use only; intended to monitor effectiveness of diabetes control; not for diagnosis or screening of diabetes or use on neonates",
    "fda_folder": "Clinical Chemistry"
}